An unbalanced portfolio.
An excellent demonstration of how meaningful and valuable conferences devoted to the topic of project and portfolio management in the pharmaceutical industry can be, was given at an event organized in Barcelona, September 2008. Thus, over this 2-day meeting the delegates were updated on the state of the art in this wide-reaching area from speakers representing an array of companies; from small, relatively new players, via mid-sized, to established large and big pharmas. One common theme that emerged was the importance of assessing the value of drug projects as correctly as possible, especially under the current financial climate and the many challenges facing the industry. Furthermore, experiences from constructing portfolios with the aim to minimize risk and maximize return on investment were shared alongside mathematical approaches to obtain the data required for this purpose and accounts of the pleasures and hardships working in a global context and in partnership constellations.
Federsel
Hans-Jurgen
HJ
Global Process R&D, AstraZeneca, 151 85 Sodertalje, Sweden. hans-jurgen.federsel@astrazeneca.com
D003659:Decision Making, Organizational; D015195:Drug Design; D055808:Drug Discovery / Q000191:economics / Q000379:methods; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D012106:Research / Q000191:economics / Q000458:organization & administration*; D012306:Risk